Endoglin suppresses human prostate cancer metastasis

Clinical and Experimental Metastasis

Volumn 28, Issue 1, 2011, Pages 39-53

  Lakshman, Minalini ^a,d   Huang, Xiaoke ^a   Ananthanarayanan, Vijayalakshmi ^b,e   Jovanovic, Borko ^a   Liu, Yueqin ^a,f   Craft, Clarissa S ^a,g   Romero, Diana ^c   Vary, Calvin P H ^c   Bergan, Raymond C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Maine Medical Center Research Institute   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Circulating tumor cells; Endoglin; Metastasis; Prostate cancer; Transforming growth factor

Indexed keywords

ENDOGLIN; KI 67 ANTIGEN; SMAD1 PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR SOX4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER INVASION; CELL COUNT; CIRCULATION; CONTROLLED STUDY; DRUG MECHANISM; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOLECULAR MODEL; MOUSE; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; SOFT TISSUE METASTASIS; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 79951676729     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9356-6     Document Type: Article

References (52)

1. Jemal A et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
2. Zelefsky MJ et al (2008) Cancer of the Prostate. In: DeVita VT, Lawrence TS, Rosenberg sa (eds) CANCER: Principles and Practice of Oncology. Lippincott Williams & Wilkins, New York, pp 1392-1462
3. Ruoslahti E (1996) How cancer spreads. Sci Am 275(3):72-77
4. Stetler-Stevenson WG, Yu AE (2001) Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11(2):143-152 (Pubitemid 32423289)
5. Liu Y et al (2002) Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21(54):8272-8281 (Pubitemid 35477867)
6. Craft CS et al (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26(51):7240-7250 (Pubitemid 350085322)
7. Cheifetz S et al (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267(27):19027-19030
8. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685-700 (Pubitemid 36724933)
9. Jovanovic BD et al (2001) A simple analysis of gene expression and variability in gene arrays based on repeated observations. Am J Pharmacogenomics 1(2):145-152
10. Bertolino P et al (2005) Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 128 (6 Suppl): 585S-590S (Pubitemid 43054142)
11. Craft CS et al (2008) Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol Pharmacol 73(1):235-242 (Pubitemid 350294214)
12. Lakshman M et al (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68(6):2024-2032 (Pubitemid 351416590)
13. Takimoto CH et al (2003) Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12 (11 Pt 1): 1213):1213-1221 (Pubitemid 37499447)
14. Xu L et al (2009) MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst 101:1141-1155
15. ATCC (2007) Cell line verification test recommendations. ATCC Technical Bulletin No. 8, pp 1-3
16. Wyckoff JB et al (2000) A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 60(9):2504-2511 (Pubitemid 30262445)
17. Xue C et al (2006) Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66(1):192-197 (Pubitemid 43166025)
18. Lakshman M et al (2005) CD44 promotes resistance to apoptosis in murine colonic epithelium. J Cell Physiol 203(3):583-588 (Pubitemid 40629021)
19. Kelley MJ et al (2005) Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiol Biomarkers Prev 14(4):892-899 (Pubitemid 40478553)
20. Lakshman M, Subramaniam V, Jothy S (2004) CD44 negatively regulates apoptosis in murine colonic epithelium via the mitochondrial pathway. Exp Mol Pathol 76(3):196-204 (Pubitemid 38569780)
21. Ding Y et al (2006) Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer Prostatic Dis 9(4):379-391 (Pubitemid 44843131)
22. Ding Y et al (2007) The methodology used to measure differential gene expression affects the outcome. J Biomol Tech 18(5):321-330
23. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25(4):402-408 (Pubitemid 34164012)
24. Liu YQ et al (2001) Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis 4(2):81-91 (Pubitemid 32633383)
25. Rubin MA et al (2000) Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6(3):1038-1045 (Pubitemid 30159365)
26. Bellon T et al (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23(9):2340-2345 (Pubitemid 23265903)
27. Goodman OB Jr et al (2009) Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 18(6):1904-1913
28. Kasimir-Bauer S (2009) Circulating tumor cells as markers for cancer risk assessment and treatment monitoring. Mol Diagn Ther 13(4):209-215
29. Helo P et al (2009) Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 55(4):765-773
30. Sastre J et al (2008) Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 19(5):935-938 (Pubitemid 351627310)
31. Pollack A et al (2004) Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22(11):2133-2140 (Pubitemid 41095146)
32. Inoue T et al (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66(2):332-337 (Pubitemid 41138093)
33. Bubendorf L et al (1996) Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178(4):437-441 (Pubitemid 26145136)
34. Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274(2):584-594
35. Rohlff C et al (1998) Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. Prostate 37:51-59 (Pubitemid 28385185)
36. Sehgal I, Thompson TC (1999) Novel regulation of type IV collagenase (matrix metalloproteinase-9 and-2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 10(2):407-416 (Pubitemid 29156481)
37. David L, Feige JJ, Bailly S (2009) Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20(3):203-212
38. Ota T et al (2002) Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 193(3):299-318 (Pubitemid 35265950)
39. Locklin RM et al (2001) Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology. J Bone Miner Res 16(12):2192-2204 (Pubitemid 33104709)
40. Fisher KE et al (2009) MT1-MMP-and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. J Cell Sci 122 (Pt 24): 4558):4558-4569
41. Seftor EA et al (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10(1):174-196 (Pubitemid 44874300)
42. Mysliwiec P et al (2008) Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients. Folia Histochem Cytobiol 46(4):487-492
43. Fujita K et al (2009) Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 124(3):664-669
44. Takahashi N et al (2001) Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 7(3):524-532 (Pubitemid 32707974)
45. Vo MN et al (2010) Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast Cancer Res Treat 119(3):767-771
46. Uneda S et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125(6):1446-1453
47. Bernabeu C, Lopez-Novoa JM, Quintanilla M (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792(10):954-973
48. Wong VC et al (2008) Identification of an invasion and tumorsuppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer 123(12):2816-2823
49. Perez-Gomez E et al (2007) A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res 67(21):10268-10277 (Pubitemid 350070800)
50. Oxmann D et al (2008) Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 27(25):3567-3575 (Pubitemid 351793804)
51. Blanco FJ et al (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204(2):574-584 (Pubitemid 40934653)
52. Lebrin F et al (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23(20):4018-4028 (Pubitemid 39472423)